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Poster Session-II 127Primitive quiescent CD341 cells in chronic myeloid leukemia
(CML) are relatively resistant to tyrosine kinase inhibitors, which
may explain the persistence of detectable BCR-ABL transcripts fol-
lowing treatment with these agents. Conversely, allogeneic stem
cell transplantation (SCT) can eradicate residual CML, suggesting
that quiescent stem cells are eliminated by graft-versus-leukemia
(GVL) effects. We studied the progeny of CD341 cells after 4
days culture in serum-free media supplemented with interleukin-3,
interleukin-6, stem cell factor, granulocyte-colony stimulating factor
and Flt-3 ligand in 14 CML patients who subsequently received T
cell depleted SCT from their HLA-identical sibling donors. Cycling
CD34-negative and CD341, and non-cycling quiescent CD341
CML cells were isolated by fluorescence activated cell sorting. Fluo-
rescence in situ hybridization in 7 representative CML patients re-
vealed over 80% BCR-ABL positivity in both quiescent and
cycling CD341 and CD34-negative populations. The expression
of BCR-ABL was the same in both cycling and quiescent CD341
cell populations. Quiescent CD341 cells from CML patients were
lysed by natural killer (NK) cells from their donors, which had
been expanded after 11–13 days culture with interleukin-2 and irra-
diated EBV-LCL.QuiescentCD341 cells were less susceptible than
their cycling CD341 and CD34-negative counterparts to NK cyto-
toxicity. Compared to cycling populations, quiescent CD341 cells
from CML patients had higher expression of tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL) receptors. Previous
studies have demonstrated that bortezomib can sensitize malignant
cells to NK-cell TRAIL (Lundqvist et al Cancer Res 2006). Bortezo-
mib treatment of quiescent CD341 CML cells enhanced their kill-
ing by expanded donor NK cells. This increased sensitivity to NK-
cytotoxicity correlated with upregulation of TRAIL receptor DR4
on the surface of quiescent CD341 CML cells. Bortezomib did
not significantly affect the expression of MHC Class I, MIC A/B
or Fas (CD95) on CD341 quiescent or cycling cells. These results
suggest that adoptive transfer of in vitro expanded donor NK cells
with concomitant administration of bortezomib to the recipient
may enhance cytotoxicity to quiescent CD341 cells and may im-
prove NK-mediated GVL effects. This may be particularly applica-
ble to CML patients who are transplanted in more advanced stage
disease, and are at a greater risk of relapse.354
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Introduction: Corticosteroids remain the primary therapy for
aGVHD. The reported response rate to standard treatment (IV
MP 2mg/kg/day for 14 days then tapered) is 70%. Patients who
are refractory to standard treatment may be treated with high dose
MP. We evaluated the response to high dose MP in children with
aGVHD refractory to standard dose MP.
Methods:Children included in this evaluation underwent HSCT
between June 1, 2002 and July 31, 2006; did not receive MP for
aGVHD prophylaxis; developed $ grade II aGVHD; and received
MP 2mg/kg/day as initial therapy. Response to aGVHD therapy, al-
ternate aGVHD treatment, adverse effects attributed to MP and
overall outcomes were documented.
Results: 50 children (29 male; mean age 8.9yrs (range 0.3–17yrs))
developed aGVHD during the study period. The median time to di-
agnosis of aGVHD $ grade II was 18 days (range 10–60 days). 34
children had single organ involvement alone; 36 (72%) responded
to standard dose MP including 29 of 34 children with aGVHD in-
volving a single organ. Of the 14 children who failed to respond to
standard treatment, 12 children received high dose MP ($20mg/
kg/day) for 3 consecutive days followed by tapering dose. When
high dose MP was started, 10 patients had skin, 8 gut, 7 liver and 1
lung aGVHD. 11 patients had $ grade III aGVHD when high
dose MP was started. 10 patients received high dose MP at a median
of 11 days (range 3–18days) after starting standard treatment while 2patients receivedhighdoseMPafter other non-steroid therapy failed.
Only one patient with grade III aGVHD (stage 3 skin, stage 2 liver)
had complete response. 2 patients had partial response but flared
when MP was tapered. All patients who failed high dose MP needed
further salvage therapy. All children who receivedMP developed hy-
pertension and required antihypertensivemedication. 16 childrende-
veloped hyperglycemia (7 on high dose MP); 5 required insulin.
While on high-dose or tapering of high-doseMP, 5 developed severe
infection (2 fungal, 2 adenovirus, 1 bacterial). 22 out of the 36 patients
who responded to standard treatmentwere available for follow-up; 13
(60%) are alive (median follow-up:39mos). 6 children (50%) who re-
ceived high dose MP therapy died (median follow-up:46mos).
Conclusions: Children with aGVHD refractory to standard dose
MP who subsequently receive high dose MP do not respond and ex-
perience significant adverse effects. Other salvage therapy should be
considered in these patients.355
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N-acetyl-L-cysteine (NAC) is a thiol antioxidant which stimulates
glutathione synthesis in cells. Several studies indicate that NAC ex-
erts effects on the immune system in vitro, although with conflicting
results. Whereas some studies indicate that NAC has an inhibitory
effect on T cell proliferation and activation of NF-kB, others suggest
an activating effect. The ability of NAC to protect cells against oxi-
dative stress by inducing glutathione has provided a rationale for us-
ing it to prevent veno-occlusive disease of the liver and liver toxicity
after allogeneic stem cell transplantation (ASCT). Unfortunately,
a prospective randomized study failed to show a positive effect of
NAC on hepatotoxicity in ASCT patients. However, we observed
that patients who received NAC as a therapy to treat liver toxicity
(n 5 73) had an increased prevalence of acute GvHD compared to
patients who had been randomized to not receive NAC (n 5 87)
(P 5 0.04), indicating that NAC has an immunostimulatory effect
in vivo. Importantly, the NAC-treated group only had an increased
risk of grade II acute GvHD (30%) compared to the control group
(10%), whereas severe acute GvHD grades III-IV in the groups
were 8% vs 14%, respectively. These observations prompted us to
thoroughly study the effect of NAC on T cell mediated immunity
in vitro. We have found that low levels of NAC (0.4–3.2 mM) poten-
tiate T cell proliferation and upregualtion of activation markers in
response to alloantigens, whereas high concentrations (12.5–50
mM) are highly suppressive, whichmight explain the previously pub-
lished conflicting data. Furthermore, T cells that have been stimu-
lated in the presence of high concentrations of NAC (25 mM) in
a primary mixed lymphocyte reaction (MLR) respond more vigor-
ously when restimulated in a secondary MLR without NAC, com-
pared to control secondary MLR which had been cultured without
NAC during both stimulations. Preliminary data indicate that this
observation partly can be explained by that NAC render T cells
less apoptotic, and that T cells respond robustly when NAC has
been metabolized. To summarize, we have found that NAC has an
immunostimulatory effect on T cells under certain conditions,
both in vitro and in vivo. These observations might be of clinical im-
portance, as NAC potentially could be used as a therapeutic agent to
promote T cell mediated immunity in immunocompromized ASCT
patients with relapse of the underlying malignant disease.356
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